Drug intelligence / Profile preview

DNL921

Development stage: Phase 1
Lead developer: Denali Therapeutics
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

DNL921 (also known as ATV:Abeta) is an investigational therapeutic developed by Denali Therapeutics. It is designed to target amyloid beta, a key pathological protein implicated in Alzheimer's disease. The drug utilizes Denali's proprietary Transport Vehicle (TV) technology platform, which aims to enhance the delivery of therapeutics across the blood-brain barrier—a major challenge in neurodegenerative disease treatment. DNL921 is being advanced for the treatment of Alzheimer's disease and represents a novel approach by enabling more effective targeting and clearance of amyloid beta aggregates in the brain[1][5].

Other names: ATV:Abeta

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on DNL921.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNL921.

Explore the full profile